- Home
- LEGH vs AUTL Comparison
LEGH vs AUTL Comparison
Compare LEGH & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$20.85
HOLD
Current Price
$1.57
Company Overview
Basic Information| Metric | LEGH | AUTL |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 368.6M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LEGH | AUTL |
|---|---|---|
| Price | $20.85 | $1.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $25.00 | $8.33 |
| AVG Volume (30 Days) | 130.9K | ★ 3.9M |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $180,497,000.00 | $51,128,000.00 |
| Revenue This Year | N/A | $658.11 |
| Revenue Next Year | $6.07 | $91.34 |
| P/E Ratio | $10.49 | ★ N/A |
| Revenue Growth | 10.25 | ★ 406.67 |
| 52 Week Low | $18.84 | $1.11 |
| 52 Week High | $29.45 | $2.80 |
Technical Indicators
Market Signals| Indicator | LEGH | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 56.48 |
| Support Level | $20.08 | $1.46 |
| Resistance Level | $20.87 | $1.69 |
| Average True Range (ATR) | 0.64 | 0.09 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 97.61 | 73.33 |
Price Performance
Historical Comparison LEGH
AUTL
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.